<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03884049</url>
  </required_header>
  <id_info>
    <org_study_id>METC 2018-081</org_study_id>
    <secondary_id>2018-081</secondary_id>
    <nct_id>NCT03884049</nct_id>
  </id_info>
  <brief_title>Neovascularization Embolisation for Knee Osteoarthritis.(NEO)</brief_title>
  <acronym>NEO</acronym>
  <official_title>Novel Transcatheter Arterial Embolization for Treatment of Knee Osteoarthritis: a Randomized Sham-controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Erasmus Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>William Cook Europe</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Stichting Coolsingel</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Erasmus Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this double blind randomized sham controlled study the investigators want to establish the
      efficacy of transcatheter arterial embolization of neovessels for patients with symptomatic
      mild to moderate knee osteoarthritis after 4 months compared to a sham-embolization.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rationale:

      Transcatheter arterial embolization has recently been proposed as an efficacious therapy for
      therapy-resistant osteoarthritis of the knee, providing substantial pain reduction at
      short-term as well as long-term follow-up up till 4 years.

      A potential working mechanism of treatment effect is that the normalization of the amount of
      blood vessels and blood flow achieved by embolization reduces inflammation, resulting in pain
      reduction

      Objective:

      The main objective is to assess whether transcatheter arterial embolization of neovessels in
      patients with symptomatic knee OA results in significant pain reduction after 4 months
      compared to sham treatment.

      The investigators hypothesize that novel transcatheter arterial embolization of neovessels is
      a feasible, effective, and safe treatment for patients with symptomatic radiographic knee OA,
      resulting in significant improvement of pain symptoms in a period of 4 months follow-up
      compared to sham embolization.

      Secondary objectives are

        1. to assess whether reduction of neovessels is related to pain relief,

        2. to explore whether decrease of inflammation is a mediating factor between neovessel
           reduction and pain relief,

        3. to assess whether transcatheter arterial embolization reduction of neovessels decreases
           peripheral and central pain sensitization and

        4. to assess whether transcatheter arterial embolization improve the outcome at 1, 4, 8 and
           12 months compared to placebo of the: ICOAP, painDETECT, EQ-5D-5L questionnaires and NRS
           for pain.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 5, 2019</start_date>
  <completion_date type="Anticipated">November 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Double-blinded randomized placebo-controlled clinical trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Double blinded</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>KOOS pain sub score</measure>
    <time_frame>4 months</time_frame>
    <description>KOOS pain sub score after 4 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total KOOS</measure>
    <time_frame>1,4,8,12 month(s)</time_frame>
    <description>Total KOOS result</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>painDETECT questionnaire</measure>
    <time_frame>1,4,8,12 month(s)</time_frame>
    <description>painDETECT questionnaire results</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICOAP questionnaire</measure>
    <time_frame>1,4,8,12 month(s)</time_frame>
    <description>ICOAP questionnaire results</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Score 0-10 Numerical Rating Scale (NRS)</measure>
    <time_frame>1,4,8,12 month(s)</time_frame>
    <description>The Numeric Pain Rating Scale (NPRS) is a unidimensional measure of pain intensity in adults.
The 11-point numeric scale ranges from '0' representing one pain extreme (e.g. &quot;no pain&quot;) to '10' representing the other pain extreme (e.g. &quot;pain as bad as you can imagine&quot; or &quot;worst pain imaginable&quot;).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EQ-5D-5L questionnaire</measure>
    <time_frame>1,4,8,12 month(s)</time_frame>
    <description>EQ-5D-5L questionnaire results</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pressure pain threshold testing</measure>
    <time_frame>1,4,8,12 month(s)</time_frame>
    <description>Pressure pain threshold testing results</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Knee MRI</measure>
    <time_frame>1 and 4 month(s)</time_frame>
    <description>Knee MRI scan results</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">58</enrollment>
  <condition>Osteoarthritis, Knee</condition>
  <arm_group>
    <arm_group_label>Embolization group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group undergoes transcatheter arterial embolization of neovessels around the knee.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham Embolization Group</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Group undergoes sham embolization</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Embolization</intervention_name>
    <description>transcatheter arterial embolization of neovessels around the knee</description>
    <arm_group_label>Embolization group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Sham embolization</intervention_name>
    <description>Sham transcatheter arterial embolization of neovessels in the knee</description>
    <arm_group_label>Sham Embolization Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age.≥18 years

          -  Knee pain for a duration of ≥ 6 months

          -  Knee pain (numeric rating scale ≥4 - ≤8) on at least half of the days in the preceding
             month at time of inclusion.

          -  There is insufficient response of conservative treatment for at least 6 months

          -  Radiographic knee osteoarthritis (radiographic Kellgren and Lawrence grade 1-3)

        Exlusion criteria:

          -  Contra-indications for MRI (e.g. metallic foreign bodies, etc.)

          -  Contra-indications for angiography

          -  Renal insufficiency, checked with blood sample test (GFR &lt; 30 ml/min/1, 73 m2);

          -  Known allergy to contrast agents;

          -  Patient has known allergies to barium sulfate, 3-aminopropyltrialkoxysilane,
             polyphosphazene

          -  Women who are pregnant or lactating

          -  Intermittent claudication of affected limb

          -  Intra articular injections in the ipsilateral knee less than 6 months ago

          -  On the waiting list for joint replacement surgery

          -  Amitriptyline usage.

          -  Patient has known allergies to barium sulfate, 3-aminopropyltrialkoxysilane,
             polyphosphazene.

          -  Insufficient command of the Dutch or English language.

          -  Legally incompetent adults.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edwin Edwin, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Erasmus Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Adriaan Moelker, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Erasmus Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Edwin Oei, MD, PhD</last_name>
    <phone>31 10 7040619</phone>
    <email>e.oei@erasmusmc.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tijmen A Zadelhof, PhD student</last_name>
    <phone>31 10 7030420</phone>
    <email>t.vanzadelhoff@erasmusmc.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>ErasmusMC</name>
      <address>
        <city>Rotterdam</city>
        <state>Zuid Holland</state>
        <zip>3015CE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>March 19, 2019</study_first_submitted>
  <study_first_submitted_qc>March 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 21, 2019</study_first_posted>
  <last_update_submitted>July 29, 2019</last_update_submitted>
  <last_update_submitted_qc>July 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Erasmus Medical Center</investigator_affiliation>
    <investigator_full_name>Dr. Edwin Oei</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <keyword>ranscatheter</keyword>
  <keyword>embolization</keyword>
  <keyword>osteoarthritis</keyword>
  <keyword>arterial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Not as yet.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

